Although anti–TNF-α therapy appears to increase the weight and BMI of patients, this effect does not appear in patients treated with anti–IL-12/23 therapy with weight-adjusted doses, suggesting that ustekinumab could be considered to treat overweight and obese patients with psoriasis (Wu et al., 2020). Here, TNF is linked to psoriasis.